<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Nutrition Journal - Latest articles</title>
		<link>http://www.nutritionj.com</link>
		<description>The latest articles from Nutrition Journal (ISSN 1475-2891) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/20"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/19"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/18"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/17"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/14"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/13"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/12"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionj.com/content/7/1/11"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.nutritionj.com/content/7/1/20">
            
            <title>Clinical and biochemical effects of a combination botanical product (ClearGuardTM) for allergy: a pilot randomized double-blind placebo-controlled trial</title>
			<description>Background:
Botanical products are frequently used for treatment of nasal allergy. Three of these substances, Cinnamomum zeylanicum, Malpighia glabra, and Bidens pilosa, have been shown to have a number of anti-allergic properties in-vitro. The current study was conducted to determine the effects of these combined ingredients upon the nasal response to allergen challenge in patients with seasonal allergic rhinitis.
Methods:
Twenty subjects were randomized to receive the combination botanical product, (CBP) 2 tablets three times a day, loratadine, 10 mg once a day in the morning, or placebo, using a randomized, double-blinded crossover design. Following 2 days of each treatment and during the third day of treatment, subjects underwent a nasal allergen challenge (NAC), in which Nasal Symptom Scale scores (NSS) were assessed after each challenge dose and every 2 hours for 8 hours. Nasal lavage fluid was assessed for tryptase, prostaglandin D2, and leukotriene E4 concentrations and inflammatory cells.
Results:
Loratadine significantly reduced the total nasal symptom score during the NAC compared with placebo (P = 0.04) while the CBP did not. During the 8 hour period following NAC, loratadine and the CBP both reduced NSS compared with placebo (P = 0.034 and P = 0.029, respectively). Analysis of nasal lavage fluid demonstrated that the CBP prevented the increase in prostaglandin D2 release following NAC, while neither loratadine nor placebo had this effect. None of the treatments significantly affected tryptase or leukotriene E4 release or inflammatory cell infiltration.
Conclusions:
The CBP significantly reduced NSS during the 8 hours following NAC and marginally inhibited the release of prostaglandin D2 into nasal lavage fluid, suggesting potential clinical utility in patients with allergic rhinitis.</description>
			<link>http://www.nutritionj.com/content/7/1/20</link>
			
			 	<dc:creator>Jonathan Corren, Marc Lemay, Yumei Lin, Lisa Rozga and R. Keith Randolph</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:20</dc:source>
			<dc:date>2008-07-14</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-20</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/19">
            
            <title>The relationship between bioelectrical impedance phase angle and subjective global assessment in advanced colorectal cancer</title>
			<description>Background:
Bioelectrical Impedance (BIA) derived phase angle is increasingly being used as an objective indicator of nutritional status in advanced cancer. Subjective Global Assessment (SGA) is a subjective method of nutritional status. The objective of this study was to investigate the association between BIA derived phase angle and SGA in advanced colorectal cancer.
Methods:
We evaluated a case series of 73 stages III and IV colorectal cancer patients. Patients were classified as either well-nourished or malnourished using the SGA. BIA was conducted on all patients and phase angle was calculated. The correlation between phase angle and SGA was studied using Spearman correlation coefficient. Receiver Operating Characteristic curves were estimated using the non-parametric method to determine the optimal cut-off levels of phase angle.
Results:
Well-nourished patients had a statistically significantly higher (p = 0.005) median phase angle score (6.12) as compared to those who were malnourished (5.18). The Spearman rank correlation coefficient between phase angle and SGA was found to be 0.33 (p = 0.004), suggesting better nutritional status with higher phase angle scores.A phase angle cut-off of 5.2 was 51.7% sensitive and 79.5% specific whereas a cut-off of 6.0 was 82.8% sensitive and 54.5% specific in detecting malnutrition. Interestingly, a phase angle cut-off of 5.9 demonstrated high diagnostic accuracy in males who had failed primary treatment for advanced colorectal cancer.
Conclusion:
Our study suggests that bioimpedance phase angle is a potential nutritional indicator in advanced colorectal cancer. Further research is needed to elucidate the optimal cut-off levels of phase angle that can be incorporated into the oncology clinic for better nutritional evaluation and management.</description>
			<link>http://www.nutritionj.com/content/7/1/19</link>
			
			 	<dc:creator>Digant Gupta, Christopher G Lis, Sadie L Dahlk, Jessica King, Pankaj G Vashi, James F Grutsch and Carolyn A Lammersfeld</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:19</dc:source>
			<dc:date>2008-06-30</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-19</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>19</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/18">
            
            <title>Effects of social approval bias on self-reported fruit and vegetable consumption: a randomized controlled trial</title>
			<description>Background:
Self-reports of dietary intake in the context of nutrition intervention research can be biased by the tendency of respondents to answer consistent with expected norms (social approval bias). The objective of this study was to assess the potential influence of social approval bias on self-reports of fruit and vegetable intake obtained using both food frequency questionnaire (FFQ) and 24-hour recall methods.
Methods:
A randomized blinded trial compared reported fruit and vegetable intake among subjects exposed to a potentially biasing prompt to that from control subjects. Subjects included 163 women residing in Colorado between 35 and 65 years of age who were randomly selected and recruited by telephone to complete what they were told would be a future telephone survey about health. Randomly half of the subjects then received a letter prior to the interview describing this as a study of fruit and vegetable intake. The letter included a brief statement of the benefits of fruits and vegetables, a 5-A-Day sticker, and a 5-a-Day refrigerator magnet. The remainder received the same letter, but describing the study purpose only as a more general nutrition survey, with neither the fruit and vegetable message nor the 5-A-Day materials. Subjects were then interviewed on the telephone within 10 days following the letters using an eight-item FFQ and a limited 24-hour recall to estimate fruit and vegetable intake. All interviewers were blinded to the treatment condition.
Results:
By the FFQ method, subjects who viewed the potentially biasing prompts reported consuming more fruits and vegetables than did control subjects (5.2 vs. 3.7 servings per day, p &lt; 0.001). By the 24-hour recall method, 61% of the intervention group but only 32% of the control reported eating fruits and vegetables on 3 or more occasions the prior day (p = 0.002). These associations were independent of age, race/ethnicity, education level, self-perceived health status, and time since last medical check-up.
Conclusion:
Self-reports of fruit and vegetable intake using either a food frequency questionnaire or a limited 24-hour recall are both susceptible to substantial social approval bias. Valid assessments of intervention effects in nutritional intervention trials may require objective measures of dietary change.</description>
			<link>http://www.nutritionj.com/content/7/1/18</link>
			
			 	<dc:creator>Tracy M Miller, Madiha F Abdel-Maksoud, Lori A Crane, Al C Marcus and Tim E Byers</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:18</dc:source>
			<dc:date>2008-06-27</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-18</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/17">
            
            <title>Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary</title>
			<description>There has been considerable investigation of the potential for soyfoods to reduce risk of cancer, and in particular cancer of the breast. Most interest in this relationship is because soyfoods are essentially a unique dietary source of isoflavones, compounds which bind to estrogen receptors and exhibit weak estrogen-like effects under certain experimental conditions. In recent years the relationship between soyfoods and breast cancer has become controversial because of concerns &#8211; based mostly on in vitro and rodent data &#8211; that isoflavones may stimulate the growth of existing estrogen-sensitive breast tumors. This controversy carries considerable public health significance because of the increasing popularity of soyfoods and the commercial availability of isoflavone supplements. In this analysis and commentary we attempt to outline current concerns regarding the estrogen-like effects of isoflavones in the breast focusing primarily on the clinical trial data and place these concerns in the context of recent evidence regarding estrogen therapy use in postmenopausal women. Overall, there is little clinical evidence to suggest that isoflavones will increase breast cancer risk in healthy women or worsen the prognosis of breast cancer patients. Although relatively limited research has been conducted, and the clinical trials often involved small numbers of subjects, there is no evidence that isoflavone intake increases breast tissue density in pre- or postmenopausal women or increases breast cell proliferation in postmenopausal women with or without a history of breast cancer. The epidemiologic data are generally consistent with the clinical data, showing no indication of increased risk. Furthermore, these clinical and epidemiologic data are consistent with what appears to be a low overall breast cancer risk associated with pharmacologic unopposed estrogen exposure in postmenopausal women. While more research is required to definitively allay concerns, the existing data should provide some degree of assurance that isoflavone exposure at levels consistent with historical Asian soyfood intake does not result in adverse stimulatory effects on breast tissue.</description>
			<link>http://www.nutritionj.com/content/7/1/17</link>
			
			 	<dc:creator>Mark J Messina and Charles E Wood</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:17</dc:source>
			<dc:date>2008-06-03</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-17</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/16">
            
            <title>Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study</title>
			<description>Background:
The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on cardiovascular protective properties in overweight and normal weight adults diagnosed with osteoarthritis of the knee.
Methods:
An 8-week, placebo-controlled, randomized, double-blind study was conducted with four groups, comparing the effects of NP 06-1 to placebo in overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; Phellodendron amurense bark and Citrus sinensis peel) or matching placebo was given in a dose of two capsules (370 mg each) twice daily. The outcome measures reported are lipid levels, weight, BMI, blood pressure and fasting glucose. Analyses of variance were used to compare changes of physiological measures over the trial period and between groups.
Results:
Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. NP 06-1 administration was associated with a general improvement in lipid levels. Both the overweight and normal weight treatment groups had significant reductions in triglycerides and LDL-cholesterol, as well as a significant increase in HDL-cholesterol compared to their respective control groups.Overall there were decreases in blood pressure in both overweight and normal weight treatment groups compared to respective placebo groups. There was also a significant decrease in fasting glucose levels in the overweight treatment group compared to the start of the study and to the overweight placebo group. There was no change in fasting blood sugar for the normal weight groups.Both overweight and normal weight treatment groups lost a significant amount of weight compared to their respective placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks, which was associated with a significant loss in BMI over time.
Conclusion:
In this pilot study NP 06-1 had a beneficial effect on cardiovascular risk factors; namely lipid levels, blood pressure and fasting glucose levels. Administration of NP 06-1 was also associated with weight loss.</description>
			<link>http://www.nutritionj.com/content/7/1/16</link>
			
			 	<dc:creator>Julius Oben, Ebangha Enonchong, Shil Kothari, Walter Chambliss, Robert Garrison and Deanne Dolnick</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:16</dc:source>
			<dc:date>2008-05-20</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-16</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/15">
            
            <title>Lower energy expenditures in infants from obese biological mothers</title>
			<description>Background:
Previous studies in adults have found that a lower resting metabolic rate is a predictor of future body weight gain.
Methods:
To determine if energy expenditures are reduced in infants born to obese mothers, 21 healthy infants (3.9 &#177; 1.9 months) born to lean (n = 7, BMI &lt; 25 kg/m2), overweight (n = 7, BMI between 25&#8211;30) and obese (n = 7, BMI>30) mothers, respectively, participated in this study. Measurements of infant weight, length and skin-fold thicknesses, and mother's weight and height were obtained. Infant energy expenditure was measured for 4-hours using the Enhanced Metabolic Testing Activity Chamber. Metabolic data were extrapolated to 24-hours and adjusted for differences in age and body composition using linear regression analysis (SPSS, version 13) and expressed as kcal/day. Differences between the three groups were determined by one way ANOVA with the Bonferroni Post Hoc test procedure (p &lt; 0.05).
Results:
Infants born to obese mothers had a greater BMI (16.7 &#177; 1.2) than those from both the overweight (15.3 &#177; 1.4, p &lt; 0.05) and lean groups (15.1 &#177; 1.3; p &lt; 0.05). The infants of obese mothers had greater body fat (26.8 &#177; 2.1) than those from the overweight group (22.4 &#177; 5.0, p &lt; 0.06). Infant BMI correlated (r = 0.53; p &lt; 0.01) with that of their mothers. Extrapolated 24-h EE (kcal/d) correlated with fat-free mass (r = 0.94; p &lt; 0.01). Infants extrapolated 24-h EE from both obese (472.1 &#177; 30.7 kcal/d; p &lt; 0.05) and overweight groups (471.8 &#177; 39.5; p &lt; 0.05) were lower than those of the lean group (532.4 &#177; 30.7).
Conclusion:
Lower extrapolated 24-h energy expenditure was present in infants of overweight and obese biological mothers during the first three to six months of life. Furthermore, these infants showed increased BMI and body fat. If these changes are unchecked future childhood obesity may result.</description>
			<link>http://www.nutritionj.com/content/7/1/15</link>
			
			 	<dc:creator>Russell Rising and Fima Lifshitz</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:15</dc:source>
			<dc:date>2008-05-16</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-15</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/14">
            
            <title>Evaluation of metabolic syndrome in adults of Talca city, Chile</title>
			<description>Objective-Insulin resistance (IR) is an important risk factor for type 2 Diabetes Mellitus (DM2) and cardiovascular disease (CVD). Metabolic Syndrome (MS) is a clustering of metabolic alterations associated to IR; however, there is no international consensus for defining its diagnosis. Our objective was to evaluate the prevalence and characteristics of MS identified by the ATP III and IDF criteria in adults from Talca city.Research and methods-We studied 1007 individuals, aged 18&#8211;74, and residents from Talca. MS subjects were defined according to ATP III (three altered factors) and IDF criteria (patients with waist circumference >80/90 cm (W/M) and two others altered factors).Results-The prevalence of metabolic syndrome according to the IDF and ATP III criteria was 36.4% and 29.5%, respectively after adjustment for age and sex. The agreement for both criteria was 89%. The prevalence in men was higher than in women for both MS definitions, although not significant. MS probability increased with age, and the highest risk was in the 57&#8211;68 age group (ATP-MS) and 53&#8211;72 age group (IDF-MS). Hypertension, high triglycerides and abdominal obesity are the most frequent alterations in MS.Conclusion-MS prevalence in adults was higher when diagnosed with IDF than with ATP criterion; in both, age is directly related with the MS presence. The MS subjects showed higher levels of blood pressure, waist circumference and plasma triglycerides. Considering our results, it is worrisome that one third of our population has a high risk of developing DM2 and CVD in the future.</description>
			<link>http://www.nutritionj.com/content/7/1/14</link>
			
			 	<dc:creator>Veronica Mujica, Elba Leiva, Gloria Icaza, Nora Diaz, Miguel Arredondo, Rodrigo Moore-Carrasco, Roxana Orrego, Marcela V&#225;squez and Ivan Palomo</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:14</dc:source>
			<dc:date>2008-05-15</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-14</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/13">
            
            <title>The effect of walnut intake on factors related to prostate and vascular health in older men</title>
			<description>Background:
Tocopherols may protect against prostate cancer and cardiovascular disease (CVD).
Methods:
We assessed the effect of walnuts, which are rich in tocopherols, on markers of prostate and vascular health in men at risk for prostate cancer. We conducted an 8-week walnut supplement study to examine effects of walnuts on serum tocopherols and prostate specific antigen (PSA). Subjects (n = 21) consumed (in random order) their usual diet +/- a walnut supplement (75 g/d) that was isocalorically incorporated in their habitual diets. Prior to the supplement study, 5 fasted subjects participated in an acute timecourse experiment and had blood taken at baseline and 1, 2, 4, and 8 h after consuming walnuts (75 g).
Results:
During the timecourse experiment, triglycerides peaked at 4 h, and gamma-tocopherol (&#947;-T) increased from 4 to 8 h. Triglyceride &#8211; normalized &#947;-T was two-fold higher (P = 0.01) after 8 versus 4 h. In the supplement study, change from baseline was +0.83 &#177; 0.52 &#956;mol/L for &#947;-T, -2.65 &#177; 1.30 &#956;mol/L for alpha-tocopherol (&#945;-T) and -3.49 &#177; 1.99 for the tocopherol ratio (&#945;-T: &#947;-T). A linear mixed model showed that, although PSA did not change, the ratio of free PSA:total PSA increased and approached significance (P = 0.07). The &#945;-T: &#947;-T ratio decreased significantly (P = 0.01), partly reflecting an increase in serum &#947;-T, which approached significance (P = 0.08).
Conclusion:
The significant decrease in the &#945;-T: &#947;-T ratio with an increase in serum &#947;-T and a trend towards an increase in the ratio of free PSA:total PSA following the 8-week supplement study suggest that walnuts may improve biomarkers of prostate and vascular status.</description>
			<link>http://www.nutritionj.com/content/7/1/13</link>
			
			 	<dc:creator>Kim J Spaccarotella, Penny M Kris-Etherton, William L Stone, Deborah M Bagshaw, Valerie K Fishell, Sheila G West, Frank R Lawrence and Terryl J Hartman</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:13</dc:source>
			<dc:date>2008-05-02</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-13</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/12">
            
            <title>The botanical integrity of wheat products influences the gastric distention and satiety in healthy subjects</title>
			<description>Background:
Maintenance of the botanical integrity of cereal kernels and the addition of acetic acid (as vinegar) in the product or meal has been shown to lower the postprandial blood glucose and insulin response and to increase satiety. However, the mechanism behind the benefits of acetic acid on blood glucose and satiety is not clear. We hypothesized that the gastric emptying rate could be involved. Thus, the aim of this study was to evaluate the possible influence of maintained botanical integrity of cereals and the presence of acetic acid (vinegar) on gastric emptying rate (GER), postprandial blood glucose and satiety.
Methods:
Fifteen healthy subjects were included in a blinded crossover trial, and thirteen of the subjects completed the study. Equicarbohydrate amounts of the following wheat-based meals were studied: white wheat bread, whole-kernel wheat bread or wholemeal wheat bread served with white wine vinegar. The results were compared with a reference meal consisting of white wheat bread without vinegar. The GER was measured with standardized real-time ultrasonography using normal fasting blood glucose &lt;6.1 mmol/l or plasma glucose &lt;7.0 mmol/l as an inclusion criterion. The GER was calculated as the percentage change in the antral cross-sectional area 15 and 90 minutes after ingestion of the various meals. Satiety scores were estimated and blood glucose was measured before and 15, 30, 45, 60, 90 and 120 min after the start of the meal.
Results:
The whole-kernel wheat bread with vinegar resulted in significantly higher (&lt;0.05) satiety than the wholemeal wheat bread and white wheat bread with vinegar and the reference bread. Wheat fiber present in the wholemeal wheat bread, or the presence of wheat kernels per se, did not affect the postprandial blood glucose or GER significantly compared with white wheat bread, neither did the addition of vinegar to white bread affect these variables. There was no correlation found between the satiety with antral areas or GER
Conclusion:
The present study shows higher satiety after a whole-kernel wheat bread meal with vinegar. This may be explained by increased antral distension after ingestion of intact cereal kernels but, in this study, not by a lower gastric emptying rate or higher postprandial blood glucose response.Trial registrationNTR1116</description>
			<link>http://www.nutritionj.com/content/7/1/12</link>
			
			 	<dc:creator>Joanna Hlebowicz, Sandra Lindstedt, Ola Bj&#246;rgell, Peter H&#246;glund, Lars-Olof Alm&#233;r and Gassan Darwiche</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:12</dc:source>
			<dc:date>2008-04-27</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-12</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionj.com/content/7/1/11">
            
            <title>Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial</title>
			<description>Background:
Recent research has established correlations between stress, anxiety, insomnia and excess body weight and these correlations have significant implications for health. This study measured the effects of a proprietary blend of extracts of Magnolia officinalis and Phellodendron amurense (Relora&#174;) on anxiety, stress and sleep in healthy premenopausal women.
Methods:
This randomized, parallel, placebo controlled clinical study was conducted with healthy, overweight (BMI 25 to 34.9), premenopausal female adults, between the ages of 20 and 50 years, who typically eat more in response to stressful situations and scores above the national mean for women on self-reporting anxiety. The intervention was Relora (250 mg capsules) or identical placebo 3 times daily for 6 weeks. Anxiety as measured by the Spielberger STATE-TRAIT questionnaires, salivary amylase and cortisol levels, Likert Scales/Visual Analog Scores for sleep quality and latency, appetite, and clinical markers of safety. The study was conducted by Miami Research Associates, a clinical research organization in Miami, FL.
Results:
The intent-to-treat population consisted of 40 subjects with 26 participants completing the study. There were no significant adverse events. Relora was effective, in comparison to placebo, in reducing temporary, transitory anxiety as measured by the Spielberger STATE anxiety questionnaire. It was not effective in reducing long-standing feelings of anxiety or depression as measured using the Spielberger TRAIT questionnaire. Other assessments conducted in this study including salivary cortisol and amylase levels, appetite, body morphology and sleep quality/latency were not significantly changed by Relora in comparison to placebo.
Conclusion:
This pilot study indicates that Relora may offer some relief for premenopausal women experiencing mild transitory anxiety. There were no safety concerns or significant adverse events observed in this study.</description>
			<link>http://www.nutritionj.com/content/7/1/11</link>
			
			 	<dc:creator>Douglas S Kalman, Samantha Feldman, Robert Feldman, Howard I Schwartz, Diane R Krieger and Robert Garrison</dc:creator>
			
			<dc:source>Nutrition Journal 2008, 7:11</dc:source>
			<dc:date>2008-04-21</dc:date>
			<dc:identifier>doi:10.1186/1475-2891-7-11</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition Journal</prism:publicationName>
					
			
							
					<prism:issn>1475-2891</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
